This is a Phase 1/2, open-label, randomized, dose finding and dose expansion study to evaluate the safety, preliminary efficacy, and PK of gedatolisib in combi…

mCRPC (Metastatic Castration-resistant Prostate Cancer)Genital Diseases, MaleUrogenital Diseases, Male+3 more

~Estimated

~$10 – $8,750

Celcuity IncNCT06190899

Phase 2

Supraphysiologic Testosterone Priming Induces Darolutamide Extended Response Via Modulation of ANdrogen Receptor (the SPIDERMAN Trial)

The objective of this study is to determine the safety and clinical effects of alternating pharmacologic (i.e. supraphysiologic) testosterone therapy with daro…

Metastatic Castration-resistant Prostate Cancer

~Estimated

~$10 – $6,250

Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsNCT07142551

← PreviousPage 6 of 6Next →